# Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma

**Authors:** Muhammad Hashim, Gerald Timelthaler, Dominik Kirchhofer, Beatrice Irina Kudlacek, Berta Mosleh, Katharina Sinn, Ezzat Mohamed Awad, Mir Alireza Hoda, Bettina Grasl-Kraupp, Balazs Dome, Walter Berger, Georg Krupitza, Karin Schelch, Michael Grusch

PMC · DOI: 10.3390/antiox15010121 · Antioxidants · 2026-01-17

## TL;DR

This study shows that reactive oxygen species promote cell migration and immune evasion in pleural mesothelioma through YB-1 phosphorylation.

## Contribution

The study reveals a novel mechanism by which ROS drive PM progression via YB-1 phosphorylation and immune checkpoint expression.

## Key findings

- ROS exposure increases cell migration and elongation in mesothelial and PM cells.
- Phosphorylation of YB-1 and upregulation of PD-L1/PD-L2 are linked to ROS-induced effects.
- Inhibiting YB-1 phosphorylation reverses ROS-driven migration and immune evasion.

## Abstract

Reactive oxygen species (ROS)-induced aberrant oncogenic signalling has been proposed to mediate the progression and development of pleural mesothelioma (PM). In this study, we demonstrate how ROS promote oncogenic signalling, especially in the context of cell migration and immune evasion via YB-1 phosphorylation in mesothelial and PM cell models. Xanthine (X)- and xanthine oxidase (XO)-generated ROS exposure led to increased migration and a more elongated cell shape in mesothelial and PM cells in live-cell videomicroscopy analyses. These effects were associated with the enhanced phosphorylation of ERK, AKT, and YB-1 and the elevated gene expression of PD-L1 and PD-L2, which were analysed with immunoblotting and quantitative real-time RT-PCR, respectively. The pharmacological inhibition of AKT (ipatasertib), MEK (trametinib), and RSK (BI-D1870) resulted in the reversal of ROS-induced effects, with the strongest effects observed upon the inhibition of YB-1 phosphorylation by BI-D1870. The results suggest that ROS exposure has a strong impact on cell migration and immune evasion not only in PM cells but also in mesothelial cells, from which PM arises. Interfering with ROS-responsive kinase pathways, particularly YB-1 phosphorylation, could counteract pro-migratory and immune-evasive effects in PM.

## Linked entities

- **Genes:** YBX1 (Y-box binding protein 1) [NCBI Gene 4904], CD274 (CD274 molecule) [NCBI Gene 29126], PDCD1LG2 (programmed cell death 1 ligand 2) [NCBI Gene 80380], EPHB2 (EPH receptor B2) [NCBI Gene 2048], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609], RPS6KA1 (ribosomal protein S6 kinase A1) [NCBI Gene 6195]
- **Chemicals:** xanthine (PubChem CID 1188), ipatasertib (PubChem CID 24788740), trametinib (PubChem CID 11707110), BI-D1870 (PubChem CID 25023738)
- **Diseases:** pleural mesothelioma (MONDO:0003308)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PDCD1LG2 (programmed cell death 1 ligand 2) [NCBI Gene 80380] {aka B7DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2}, RPS6KA2 (ribosomal protein S6 kinase A2) [NCBI Gene 6196] {aka HU-2, MAPKAPK1C, RSK, RSK3, S6K-alpha, S6K-alpha2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, YBX1 (Y-box binding protein 1) [NCBI Gene 4904] {aka BP-8, CBF-A, CSDA2, CSDB, DBPB, EFI-A}
- **Diseases:** PM (MESH:D000086002)
- **Chemicals:** ipatasertib (MESH:C583616), X (-), Xanthine (MESH:D019820), trametinib (MESH:C560077), ROS (MESH:D017382), BI-D1870 (MESH:C516541)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12838097/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12838097/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12838097/full.md

---
Source: https://tomesphere.com/paper/PMC12838097